Serum cytokine levels in breast cancer patients during neoadjuvant treatment with bevacizumab
DOI: 10.1080/2162402X.2018.1457598
Anne-Lise B？rresen-Dale,
Bj？rn Naume,
Hedda von der Lippe Gythfeldt,
Jon Amund Kyte,
Manuela Zucknick,
Marianne Nome,
Olav Engebraaten,
Olga Troyanskaya,
Ruth Dannenfelser,
Shakila Jabeen,
Surendra Kumar,
Thomas Fleischer,
Torben Lüders,
Vessela Kristensen,
Xavier Tekpli
Keywords: Bevacizumab, VEGF-A, neoadjuvant, cytokines, immunity
Abstract:
Full-Text
